Results: Continuous antipsychotic treatment regardless of class was associated with improvement on verbal fluency, executive functions, and visual and verbal memory. The variable "type of antipsychotic" did not predict the improvement of performance in any of the neuropsychological tests, as assessed using regression analyses. However, intake of anticholinergic drugs seems to predict cognitive changes significantly. Conclusions: In the absence of other reasons to change ongoing treatment, which include negative or affective symptoms or lack of compliance with the regimen, the switch from typical APD at low or moderate doses to atypical APDs is not justified if based solely on the expectation of a more favorable cognitive outcome. Abstract Objective: For evidence-based activities for psychiatric rehabilitation in patients with chronic schizophrenia, preceding investigation to assess the pattern or characteristic on neuroplasticity is necessary. For this purpose, this study evaluated short-term response of serum Brain-Derived Neurotrophic Factor (sBDNF) to the quantified stimuli applied with repetitive Transcranial Magnetic Stimulation (rTMS). Methods: Right-handed twenty inpatients, with chronic schizophrenia, on stable medication whose minimum duration of illness was 10 years were recruited. The handedness was assessed using Edinburgh Handedness Inventory. Consecutive 10 weekday sessions with 20 Hz rTMS (a total of 20,000 stimuli) were applied over the left dorsolateral prefrontal cortex at 100% of motor threshold. There was no change in the medication for at least 2 week before enrollment and 4 weeks thereafter. Serum Prolactin level was co-measured for the reference of stable medication. Primary outcome measure was the change in the mean concentration of duplicated sBDNF(pg/ml). Clinical severity or change was measured using the Clinical Global Impression scale (CGI) and the Positive and Negative Symptom Scale (PANSS). Results: Eighteen participants (male, 10; female, 8) completed the study and were analyzed. The mean(SD) of chlorpromazine equivalent (CPZE) of antipsychotics were 1,325.69(761.58)mg. The mean(SD) of baseline CGI-severity and total PANSS score were 4.61(0.50) and 68.44(6.05), respectively. The differences from baseline, in the level of sBDNF, just after the completion of rTMS sessions, were statistically significant (paired t-test: t = 2.245, df =17, p = 0.038). At 2 weeks after the completion of rTMS sessions, however, the significance in the level of sBDNF was not manifest (t = 1.381, df = 17, p = 0.185).
Abstract
Objective: For the treatment of the patients with treatmentresistant schizophrenia, clozapine is recommended as the drug of choice, but still causes insufficient responses in 40 to 70 % of the patients having been treated with clozapine. The electroconvulsive therapy (ECT) might be an effective and safe option increasing clinical effects. This study was aimed to explore the ECT ugmenting effects for patients with clozapine-resistant schizophrenia. Methods: By using retrospective chart reviews, nine inpatients with clozapine-resistant schizophrenia who had received ECT at Dongguk University International Hospital were recruited. Clozapine resistance is defined as persistent psychotic symptoms despite of clozapine treatment at least for 12 weeks with blood clozapine levels over 350ng/ml. The bilateral electrode was applied and MECTA spECTrum 5000Q ® was used underg eneral anesthesia. We explored the changes of psychopathology with the PANSS through ECT and the correlational factors. Results: In nine patients, the mean reduction of the PANSS total score after ECT was 17.8 (SD = 11.6) which was significant (p = 0.0092). The mean reduction rate was 25.0 % (SD = 13.0) from the baseline using 0-6 rating system. The mean clozapine doses were 388.9 (SD = 153.1) mg before ECT and 286.1 (SD = 97.7) mg after ECT with no significant changes. The mean clozapine blood levels of nine patients were 632.2 (SD = 146.9) and 552.7 (SD = 216.4) ng/mL before and after ECT respectively with no significant changes. Six (67.8 %) patients showed responses with the traditional criteria of 20% reduction used in medicationresistant schizophrenia trials. Conclusion: The result of the retrospective case series report showed that ECT augmentation on clozapine-resistance had additional clinical benefits without any persistent adverse effects. The ECT augmentation can be a favorable strategy for the treatment of clozapine-resistant schizophrenia.
